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Abstract 11 
Genome-wide association studies have identified nearly 40 genome-wide significant single nucleotide 12 
polymorphisms (SNPs) which are associated with Alzheimer’s Disease (AD). Due to the polygenicity 13 
of AD, polygenic risk scores (PRS) have shown high potential for AD risk prediction. PRSs have been 14 
shown to successfully discriminate between AD cases and controls achieving a prediction accuracy of 15 
up to 84% based on area under the receiver operating curve. The prediction accuracy in AD is higher 16 
compared with other complex genetic disorders.  17 
PRS can be restricted to SNPs which reside in biologically relevant gene-sets; the predictive value of 18 
these gene-sets in the general population is not as high as genome-wide PRS, but they may play an 19 
important role to identify mechanisms of disease development and inform biological experiments.  20 
Multiple methods are available to derive PRSs, such as selecting SNPs based on statistical evidence of 21 
association with the disease or using prior evidence for SNP selection. All methods have advantages, 22 
but PRS produced using different methodologies are often not comparable, and results should be 23 
interpreted with care. Similarly, this is true when PRS is based on different background populations.  24 
With the exponential growth in development of digital electronic devices it is easy to calculate an 25 
individual’s disease risk using public databases. A major limitation for the utility of PRSs is that the 26 
risk score is sample and method dependent. Therefore, replicability and interpretability of PRS is an 27 
important issue. PRS can be used to determine the probability of developing disease which incorporates 28 
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information about disease risk in the general population or in a specific AD risk group. It is essential 29 
to consult with genetic counsellors to ensure genetic risk is communicated appropriately.  30 
1 Introduction 31 
Genome-wide association studies (GWAS) have identified over 40 genome-wide significant single 32 
nucleotide polymorphisms (SNPs) which are associated with Alzheimer’s Disease (AD) 33 
[1][2][3][4][5]. AD, similarly to other common genetic diseases and disorders, is now recognised to be 34 
polygenic [6][7][8][9][10]. The polygenicity of AD leads to polygenic risk scores (PRS) being a 35 
successful approach in AD risk prediction. PRSs have been shown to discriminate between AD cases 36 
and controls achieving a prediction accuracy of 75-84% based on area under the receiver operating 37 
curve (AUC) in pathologically confirmed cases and controls [6][9].  38 
PRSs are advantageous for genetic prediction since genome-wide “big data” instigated by a large 39 
number of potentially contributing SNPs, are reduced into one variable which makes analysis much 40 
simpler by negating issues with overfitting and multiple testing penalties. PRSs account for the small 41 
effects of a large number of SNPs which still contribute to disease risk, successfully capturing the 42 
polygenicity of a disease. In AD, the PRS which includes all SNPs with a p-value less than or equal to 43 
0.5 shows the highest predictive ability, therefore, SNPs which show any association more than chance, 44 
may contribute to AD risk [6]. PRS can be calculated at any point in an individual’s life, so it is possible 45 
to assess disease risk prior to the onset of any disease or symptoms. This is particularly useful in late-46 
onset diseases, or diseases which likely progress while an individual is asymptomatic, such as AD. 47 
PRS has underlying requirements which result in a few limitations. Firstly it assumes independence 48 
between SNPs, therefore, SNPs in linkage disequilibrium (LD) are removed prior to analysis, resulting 49 
in loss of information. When PRS is derived for a dataset with individual genotype data, an independent 50 
summary statistic dataset is required to select the relevant SNPs. This is an increasing concern due to 51 
the amount of big data from large consortia which are produced using a meta-analysis of smaller 52 
datasets, where the independence is difficult to assess. Additionally, a p-value threshold is often used 53 
for SNP selection and this threshold may differ depending on genetic architecture of the disease and 54 
the power and quality of the data used for SNP selection (summary statistics). Without prior 55 
information, it is most common to test a number of arbitrary significance thresholds for SNP selection, 56 
and the threshold which optimises prediction accuracy in a particular dataset is taken forward, this does 57 
however, incur a multiple testing penalty and is sample-specific. PRS assumes an additive model and 58 
interactions between SNPs are not taken into account.   59 
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The PRS distribution can be divided into cases and controls; the ideal scenario would show distinct 60 
separation between the two distributions, however, there is a great deal of overlap between the two, 61 
with the majority of individuals residing in the central part of the joint distribution. It is, therefore, not 62 
straightforward to use PRS to distinguish between cases and controls in general, but the distribution 63 
tails show better separation. Finally, because a large number of SNPs are incorporated into the score, 64 
it can be labour intensive to tease out which SNPs are driving the PRS, to further understand the biology 65 
of the disease.  66 
2 Methodology 67 
In order to address the limitations highlighted in the introduction, there have been a number of methods 68 
developed to generate the PRS, these include PRSice, POLARIS, LDAK, LDpred and PRS-CS. The 69 
original method using LD pruning and p-value thresholding will be referred to as PRS(P+T) in the 70 
remainder of the manuscript. 71 
The traditional process, PRS(P+T), is to 1) remove SNPs in LD using intelligent pruning which retains 72 
SNPs with the strongest association with the disease, 2) choose SNPs which have a p-value below a 73 
defined threshold and 3) compute the PRS on the remaining SNPs as sum of the number of risk alleles, 74 
weighted by the SNP effect sizes [11]. This method is very straightforward, but potentially removes a 75 
lot of information, and requires the specification of certain parameters, such as p-value threshold and 76 
LD pruning parameters (strength of LD, and the window size where the SNPxSNP LD is calculated). 77 
However, the simplicity of this method provides easily interpretable results, and a possibility to delve 78 
further into SNP profiles to see which SNPs are contributing to the PRS and how large this contribution 79 
is. The latter can be easily extracted from the summary statistics dataset.  80 
PRSice [12][13] is a software which implements the PRS(P+T) method. It tests a number of p-value 81 
thresholds in order to find the most appropriate for the particular dataset. One of the pitfalls is that the 82 
correction for testing at multiple p-values thresholds could be overlooked when association of the most 83 
appropriate PRS with the disease or trait is reported. In addition, since the p-value selection is based 84 
on the input data, the optimal p-value threshold may not be consistent across different datasets. Finally, 85 
the selected SNPs are dependent on LD structure of the input sample and even if the same parameters 86 
for PRS(P+T) and PRSice are specified, the resulting list of SNPs is very likely to be different for 87 
different input datasets. Nevertheless, PRSice is able to process very large datasets quickly, run 88 
regression models, adjust for covariates, plot results and restrict the PRS to pathways/gene-sets. The 89 
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PRSice software is user-friendly, however, as with many softwares, it may take some investigation to 90 
understand all steps undertaken by the software, for instance, SNP removal due to ambiguity. 91 
POLARIS [14] does not require LD pruning. It accounts for LD between SNPs across the full 92 
chromosome, and creates LD-adjusted genotypes, therefore enabling all SNPs to be included in the 93 
PRS. The contribution of each SNP is recalculated, usually downweighed accounting for the number 94 
of SNPs in LD and the strength of LD between them. The p-value threshold is also not required, 95 
however the pre-selection of SNPs based on p-values or any other criteria can be imposed prior to the 96 
analysis. This method is very computationally demanding since it requires the inversion of very large 97 
SNPxSNP LD matrices. The advent of cloud computing and cheaper hardware for computers may 98 
result in these methodologies becoming more accessible.  99 
Similar to POLARIS, LDAK [15] was originally designed to adjust SNP effect sizes for LD, by 100 
reducing the contribution of SNPs in regions of high LD. Now, its primary function is to estimate SNP 101 
heritability and heritability enrichment in summary statistic data, whilst adjusting for local LD and 102 
allowing specification of the heritability model. 103 
LDpred [16] and PRS-CS [17] are both Bayesian approaches which use a prior of SNP effect sizes and 104 
heritability captured by the regional LD structure.  LDpred estimates the LD from datasets specified 105 
by the user. It can be either the same dataset which was used to generate the GWAS summary statistics 106 
or external (publicly available) data. In the current version of PRS-CS LD can only be estimated using 107 
the 1000 Genomes data [18]. While using publicly available QC-ed data (e.g. 1000 genomes) can be 108 
useful to avoid additional pre-processing steps of individual genotype data provided to the PRS-109 
software, researchers should be cautious about whether the sample used to estimate LD is 110 
representative of the summary statistic data, otherwise the adjustment for LD may be incorrect. This 111 
happens if the degree of concordance between Beta coefficients (effect sizes) for certain SNPs does 112 
not correspond to the strength and direction of LD between these SNPs. Both these methods attempt 113 
to adjust for local LD. LDpred uses a sliding window of size specified by the user, and PRS-CS divides 114 
the genome into 1703 relatively independent chunks with around 500 SNPs. Both methods have been 115 
shown to predict well, with PRS-CS outperforming LDpred whilst maintaining computational 116 
efficiency, due to the use of continuous shrinkage priors. PRS-CS gives very similar results to 117 
PRS(P+T), whereas LDpred performs slightly worse [17]. These methods have their value, but due to 118 
the complex nature of the methodologies, it is difficult to determine exactly which SNPs are most 119 
impacting the PRS.  120 
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All the methods presented compute PRS in a different manner. All of them will pick up a polygenic 121 
signal in a sample en-masse, however, when attempting to interpret and communicate the PRS value 122 
for a particular person, PRSs are difficult to compare and interpret. In order to demonstrate these 123 
discussion points in real data, we generated a PRS in the HipSci open access data [19] merged with the 124 
1000 genomes data [18], weighted with AD GWAS [5] summary statistics. Only SNPs with p<=0.5 125 
were included into the score, and the APOE region was excluded (chr19: 44.4-46.5kb). The PRS was 126 
produced using PRS (P+T), PRSice, LDpred and PRS-CS; for PRS (P+T) both HipSci and 1000 127 
genome data were used separately to estimate LD. Figure 1 shows scatterplots between the standardised 128 
PRS from PRS(P+T), PRSice, PRS-CS and LDpred. As expected, PRS(P+T) and PRSice are the most 129 
correlated approaches. PRS(P+T) is least correlated with PRS-CS and LDpred. Figure 2(A) shows the 130 
unstandardised PRS distributions generated in the same sample, with the same SNPs. Due to additional 131 
filtering by PRSice, the number of SNPs in the score differs and the distributions show a systematic 132 
shift (this is more pronounced with other softwares (see Figure 1)). An individual’s PRS generated 133 
with a different software may differ dramatically (e.g. green and black vertical lines in the positive part 134 
of the PRS distribution in Figure 2(B), indicating the same person’s PRS calculated with PRS(P+T) 135 
and PRSice). Figure 2(B) also demonstrates that PRS is sensitive to the sample used to estimate LD 136 
(compare black and red vertical lines). 137 
Since the disease architectures defined by the SNP specific disease models are likely to be different, 138 
some areas of the genome should not be modelled within the PRS. For example, amyloid protein 139 
precursor (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes contain rare highly penetrant 140 
dominant mutations [20], which if modelled as a part of PRS will demonstrate very little contribution 141 
to the disease risk. Another example is the APOE gene. APOE has a very strong genetic effect on the 142 
risk of developing AD [21]; many SNPs both within and around APOE are in high LD and show a 143 
strong statistical association with AD. Since APOE is so influential in AD, the greatest prediction 144 
accuracy of the case/control status is given when APOE is modelled separately to the PRS [6]. The 145 
number of ε4 and ε2 alleles are modelled against AD, and an APOE weighted score using the effect 146 
sizes from these models as weights is produced. This is then included in the model with PRS, where 147 
the effect of APOE is excluded from the PRS by excluding all SNPs in the region (chr19:44.4-46.5Mb). 148 
Unfortunately, standard softwares do not have the ability to select disease specific regions which ought 149 
to be modelled separately or removed from the risk score. This is an important feature which PRS 150 
methods would benefit from if incorporated into the software.  151 
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For prediction in clinical settings, methods to date do not incorporate environmental factors which 152 
would be a beneficial addition in order to further explain more disease heritability and improve 153 
prediction. Current PRS methods allow us to capture SNP-based (narrow-sense) heritability. The 154 
incorporation of environmental factors, SNP x SNP and SNP x environment interactions, rare variants 155 
and SNP-specific disease models (e.g. dominant, recessive, etc.) into the risk score may enable the 156 
capture of broad-sense heritability [22][23]. In addition, when prediction accuracy is calculated, 157 
reported and communicated, the adjustment for relevant confounding factors, population stratification 158 
in particular, have to be considered. The softwares discussed do not explicitly provide these 159 
adjustments. 160 
3 Standardisation of the PRS 161 
Comparability of PRS across different populations and datas is one of the most important issues which 162 
requires addressing. PRSs computed in different populations are not necessarily comparable; 163 
individuals may have different ethnic backgrounds, SNPs which go into the score may differ and LD 164 
structure between SNPs and SNP allele frequency will vary based on ethnicity. For example, PRS 165 
values of approximately 10 have been observed for individuals with African ancestry when the 166 
remainder of the individuals in the sample have European ancestry. To date, the PRS approach has 167 
mostly been used in European populations, but even multiple PRSs from the same population may 168 
not be comparable and require harmonisation before statistical standardisation [24]. A GWAS 169 
conducted in samples of European ancestry and used for PRS calculations in other populations, may 170 
still be predictive of the disease risk but accuracy is likely to be reduced, especially in samples of 171 
African ancestry [25]. 172 
In addition, other characteristics of a sample need to be carefully considered and accounted for. For 173 
example, since AD is an age-related disorder and disease prevalence varies depending on age, sample 174 
age may impact the PRS distribution and consequently, the prediction accuracy of the PRS. For 175 
example, AD prevalence in the general population is around 2% [26], in individuals who are aged 176 
65+ prevalence is around 10% [27] and in those aged 85+ prevalence increases to 30% [28]. It is also 177 
known that the effect of APOE is weaker in the age group 85+ [29]. Therefore, PRSs should account 178 
for such factors before statistical standardisation to ensure scores are comparable between samples 179 
and interpreted correctly. Since PRS is comprised of many risk variants of small effect, scores are 180 
Normally distributed but differences in factors (such as age and ancestry) will be reflected in the 181 
parameters of the PRS distribution (mean and standard deviation (SD)). For easy interpretation PRS 182 
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are often standardised within the study to make the mean=0 and SD=1. However this does not make 183 
the scores comparable between studies, as the original (unstandardised) mean and SD may have been 184 
different due to the specifics of the sample (age, gender, ancestry, education etc.). 185 
4 PRS for Functional Studies 186 
The identification of gene mutations that alter risk for a disease is an important route to understanding 187 
the disease mechanism. For common sporadic AD, the genetic risk is dispersed over a large number of 188 
variants and, with the exception of APOE, variants have small effects and most occur in non-coding 189 
regions where the functional variant/s are ambiguous. It is also clear that the genetics of common AD 190 
is underpinned by several components or pathways, which combine together to trigger disease.  191 
Pathway analysis of AD shows significant patterns of association implicating immunity, lipid 192 
processing, endocytosis, ubiquitination and more recently, Abeta and tau processing [5][30]. Cell type 193 
specific expression patterns have repeatedly associated the AD polygenic signal with microglia-194 
specific gene expression patterns while recent single cell dissection of AD post-mortem tissue has 195 
found microglia dysfunction as a significant early event, all identifying microglia as a key AD cell 196 
type. 197 
Most commonly, a genome-wide PRS is used across all available SNPs in the data, however, it is 198 
possible to restrict the SNPs to those within biologically relevant genes. Generally, these do not show 199 
as good prediction accuracy as the genome-wide PRS [31]. Nevertheless, to improve prediction ability, 200 
the goal is to lower the number of SNPs whilst maintaining the heritability explained by the SNPs [23], 201 
thus reducing the signal-to-noise ratio. The hope is to make the risk score much more interpretable 202 
when it is comprised of the effect of biologically important SNPs. Identifying a small number of hub 203 
genes whose perturbation can capture the larger polygenicity will also be key for therapeutically 204 
targeting these networks.  205 
PRS is often used to test the polygenicity and predictive ability of genetic data. By investigating 206 
individuals at the extremes of risk for a particular disease, PRS has other applications. For example, it 207 
is possible to create a PRS for iPSC lines, and identify and study cell lines which are at risk extremes. 208 
Since the biological experiments are quite expensive, selecting polygenic extremes can increase 209 
confidence in the cell line developing disease or remaining a control. In addition, PRS could be used 210 
to recruit individuals into clinical trials, by taking those most and least likely to develop a disease, such 211 
as AD, it is possible to increase the statistical power of your study.  212 
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The use of PRS to identify individuals at the extremes of risk is a promising approach, however, the 213 
interpretation of what it means to be in the ‘extremes’ of a risk distribution should be taken with 214 
caution. For example, if the AD polygenic risk was computed for a group of people who happen to 215 
have very low risk for AD, when this risk is standardised (to give a distribution with a mean of 0 and 216 
standard deviation of 1), some individuals may look to be positive extremes, at high risk of developing 217 
AD, however, when compared to the general population, even the positive extremes are at lower risk 218 
compared to the rest of the population. Therefore, PRS alone should not be used to determine AD risk, 219 
but instead a probability of developing disease which incorporates information about the disease 220 
prevalence in the sample and in the general population. To minimise this effect, the PRS can be 221 
standardised against a population sample, this helps to identify extremes based on the general 222 
population. To do this, your data of interest has to be merged with a population sample with similar 223 
ancestry, such as the 1000 Genomes data [18], and PRS is computed on the merged sample. The PRS 224 
is then standardised based on the mean and standard deviation of the PRS in the 1000 Genomes sample. 225 
Once individuals at the extremes of risk are identified; the most influential SNPs which drive the PRS 226 
and differentiate between positive and negative extremes can be highlighted using a GWAS of SNPs 227 
in the score, for extreme individuals.  228 
With the reducing cost of genetic testing, and the rise of companies offering this service to the public, 229 
the importance of genetic counselling is ever increasing. Much research has been done by clinicians 230 
and genetic counsellors to guide how to communicate genetic risk [32]. Individuals may prefer not to 231 
know their genetic risk of late-onset disorders such as AD, especially when there is no available 232 
intervention or treatment.  233 
Genetic prediction based upon PRS alone is insufficient for precision medicine. An approach based 234 
upon combination of genetics, environmental factors and disease biomarkers is necessary. To be able 235 
to use precision medicine, an understanding of the relationship between genotype and phenotype is 236 
required. This understanding would aid in targeting treatments and interventions, based on both the 237 
individual and disease characteristics [33][34]. 238 
5 Conclusions 239 
PRS has the potential to be a very useful resource in complex genetic diseases to suggest diagnosis in 240 
the early phase of illness when patients present with very general and non-specific symptoms. 241 
Prediction by a genetic component alone can contribute to the risk prediction accuracy, however, it is 242 
unlikely to be a stand-alone predictor of a specific disease. When results are communicated to 243 
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individuals, a careful explanation needs to be provided clearly separating a genetic test with a very 244 
high predictive value (e.g. rare fully penetrant mutations), and the PRS which alone has a limited 245 
predictive value. With the appearance of commercial companies which provide genetic data 246 
inexpensively to the general public, doctors might soon face the challenge of explaining PRS risk to 247 
individuals. The comparability of PRS values at the personal level, and therefore a unified approach to 248 
PRS generation and standardization will become more of an issue in the near future (if not already) in 249 
the digital health field. There are still a number of technical and methodological issues which need to 250 
be resolved, but as the field moves in the direction of PRS, these will likely be addressed and the utility 251 
of PRS in complex disorders will be substantial. 252 
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10 Figure Captions 355 
Figure 1) Comparison of PRS using Different Methodologies; PRS(P+T), PRSice, PRS-CS and 356 
LDpred. The PRS is computed for all individuals in HipSci [19] open access data merged with the 357 
1000 Genomes data [18], scores are weighted using AD GWAS [5] summary statistics. Only SNPs 358 
with p-values <= 0.5 are included and the APOE region (chr19: 44.4-46.5Mb) is excluded for all 359 
methods.  360 
Figure 2(A) Histogram of PRS Scores in HipSci [19]  open access data + 1000 Genomes data 361 
[18] for both PRS(P+T) and PRSice methods. Only SNPs with p-values <= 0.5 are included in the 362 
score, and a clumping threshold of 0.1 was used. Figure 2(B) Histogram displaying PRS extremes 363 
using PRS(P+T) estimating LD in HipSci [19] data. Additional vertical lines display the PRS of 364 
the same two individuals when LD is estimated from a different sample, or PRS is computed using a 365 
different method. 366 
